US LiquiBand® distribution agreements signed

Advanced Medical Solutions Grp PLC

25 October 2023

 

25 October 2023

Advanced Medical Solutions Group plc

("AMS" or the "Group")

All new US LiquiBand^® hospital distribution agreements signed

New US route-to-market strategy now operational and expected to accelerate the growth of LiquiBand^® in the US from Q4 2023

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, today announces that its new US LiquiBand^® route-to-market strategy is fully operational following the successful signing of all three hospital distribution agreements.

The structure of each of these five-year agreements has been designed to accelerate market share gains and build on the underlying momentum already established by AMS and its partners in this growing $270 million market. This new strategy will enable more product and brand differentiation that will be further strengthened following the expected approval of the Connexicon range in 2024.

Furthermore, the new route-to-market strategy has established a stronger marketing platform to enable the recently launched LiquiBand^® XL to gain traction in the US market through all three distribution channels and to build on the success that the product has already achieved, further accelerating overall LiquiBand^® growth.       

The company can confirm that each of our partners have now completed the transition to the new agreements and throughout the transition, end-user sales have not been affected and there has been no impact on customers. In addition, normal order patterns have resumed for all three partners. 

Chris Meredith, Chief Executive Officer of AMS, commented: "The successful signing of all three US distribution agreements is a significant step forward for the Group and marks an important inflection  point for the growth of the LiquiBand^® portfolio. We are extremely proud of what we have achieved to date in the US, having secured over 20 per cent of the available market. This strengthened route-to-market strategy now provides greater opportunities for us and is an important step in our ambition to more than double market share in the medium term. I look forward to building even stronger and more productive relationships with all our partners as we embark on this next phase of the LiquiBand growth story." 

- End -

For further information, please contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations
ICR Consilium	Tel: [phone]
Matthew Neal / Lucy Featherstone
Investec Bank PLC (NOMAD & Broker)	Tel: [phone]
Gary Clarence / David Anderson
HSBC Bank PLC (Broker)	Tel: [phone]
Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^®, LIQUIFIX™ and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.

 

END